Edgewood Management LLC Has $4.16 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Edgewood Management LLC decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.0% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 37,536 shares of the biopharmaceutical company’s stock after selling 2,394 shares during the period. Edgewood Management LLC’s holdings in Gilead Sciences were worth $4,162,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Loomis Sayles & Co. L P lifted its holdings in Gilead Sciences by 13,018.2% during the 2nd quarter. Loomis Sayles & Co. L P now owns 55,621 shares of the biopharmaceutical company’s stock worth $6,167,000 after purchasing an additional 55,197 shares during the last quarter. Skandinaviska Enskilda Banken AB publ grew its holdings in Gilead Sciences by 12.0% in the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 2,352,958 shares of the biopharmaceutical company’s stock valued at $260,708,000 after buying an additional 252,108 shares in the last quarter. Norges Bank bought a new position in Gilead Sciences during the 2nd quarter worth $2,150,268,000. Northwestern Mutual Wealth Management Co. increased its position in Gilead Sciences by 8.6% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 89,670 shares of the biopharmaceutical company’s stock worth $9,942,000 after buying an additional 7,080 shares during the period. Finally, Grantham Mayo Van Otterloo & Co. LLC lifted its holdings in shares of Gilead Sciences by 131.1% during the second quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 23,967 shares of the biopharmaceutical company’s stock worth $2,657,000 after buying an additional 13,597 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the sale, the insider directly owned 107,193 shares in the company, valued at approximately $13,491,310.98. The trade was a 20.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total value of $1,193,900.00. Following the completion of the transaction, the chief executive officer directly owned 581,203 shares of the company’s stock, valued at $69,389,826.17. This represents a 1.69% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 115,146 shares of company stock worth $14,012,141. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Stock Down 1.3%

GILD stock opened at $125.85 on Friday. The firm has a 50-day moving average price of $119.87 and a 200-day moving average price of $114.49. Gilead Sciences, Inc. has a 12 month low of $88.57 and a 12 month high of $128.70. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The stock has a market capitalization of $156.13 billion, a P/E ratio of 25.07, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The business had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the company earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be issued a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is 48.99%.

Analysts Set New Price Targets

A number of equities analysts recently commented on GILD shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $135.00 price target on shares of Gilead Sciences in a research report on Friday, October 31st. JPMorgan Chase & Co. raised their target price on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. Royal Bank Of Canada raised their price objective on Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a research note on Friday, October 31st. Finally, Rothschild & Co Redburn lifted their price objective on Gilead Sciences from $143.00 to $153.00 in a report on Monday, November 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $130.65.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.